We're #hiring a new Senior Scientist in Newcastle Upon Tyne, England. Apply today or share this post with your network.
Alcyomics
Biotechnology Research
Your partner for human in vitro safety and efficacy testing for immunotoxicity, neuropathy and 3D disease modelling
About us
Alcyomics is a specialist clinical research organization (CRO) supporting the pharmaceutical, biotechnology, and cosmetics industries. We offer full assay services and technical consultancy in immuno-toxicology. This is underpinned by our patented human in vitro skin assay platform, Skimune®, which provides highly sensitive detection of adverse immune reactions for pre-clinical testing of small and large molecule drugs, monoclonal antibodies, cellular therapies, cosmetic compounds etc. plus many more. Further to our immunotoxicity platforms we also specialise in 3D assay design, optimisation and validation. We have a number of 3D assays in-house such as; - Autologous skin model, Skimune 3D, for high-throughput immunotoxicity testing. - 3D innervated skin model is based in a 96-well scaffold system and has been specifically validated to detect peripheral toxicity against monoclonal antibodies and chemical insults. - Bioprinted osteo-chondral model incorporates the complex environment present in osteoarthritis. - Autologous atopic dermatitis models incorporating immune cellular function to assess compound function, efficacy and toxicity. From our state of the art facilities based within the custom built Biosphere labs in Newcastle-upon-Tyne, UK, we provide assured, experienced, professional assay support and consultancy to local, national, and international clients. Our Mission at Alcyomics is to provide robust in vitro human assays to the pharmaceutical, biotechnology, chemical and cosmetic industries that enable early detection of adverse immune reactions, reducing risk and cost in the development of drugs and compounds. www.alcyomics.com
- Website
-
www.alcyomics.com
External link for Alcyomics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Newcastle upon Tyne
- Type
- Privately Held
- Founded
- 2007
- Specialties
- Immunogenicity testing of monoclonal antibodies, Allergenicity & efficacy testing of drugs, Hypersensitivity & potency assessment of chemicals, Safety assessment of cosmeceuticals, Preclinical testing as first-in-man studies, Stratified/personalised medicine, in vitro immuno toxicology, 3D Models, Neurotoxicity, Atopic dermatitis, OECD testing, Cell line development, iPSC, Immunotoxicity, Cosmetics, Assay development , Disease modeling, Cellular therapies, and Monoclonal antibody safety
Locations
-
Primary
Get directions
Bulman House
Regent Centre , Gosforth
Newcastle upon Tyne, NE3 3LS, GB
-
Get directions
Haematological Sciences
Institute of Cellular Medicine, framlington Place
Newcastle upon Tyne, NE2 4HH, GB
Employees at Alcyomics
Updates
-
We're #hiring a new Business Development Manager in United Kingdom. Apply today or share this post with your network.
-
🔬 New Research Published! 🧬 We're excited to share that working alongside our friends at the Fredrick National Lab for Cancer Research, our latest study, "In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study," has been published in the Journal of Nanomedicine! This research focuses on the side effect known as palmar-plantar erythrodysesthesia (PPE), commonly associated with certain chemotherapy treatments. We used Alcyomics's Skimune model as the basis of a comparative in vitro analysis of nanomedicine Doxil and traditional doxorubicin to better understand their potential to cause this adverse reaction. Our findings could help preclinical development by informing safer and more effective use of nanomedicines in cancer therapy. 🔗 Check out the full publication here: https://lnkd.in/e6vgtNDf A big thank you to the incredible team at the NCI and Alcyomics for making this study happen! #research #nanomedicine #chemotherapy #oncology #pharmacology #PPE #Doxil #doxorubicin #cancerresearch #healthcare
-
Skimune® is a human skin based assay which harnesses the power of both human skin and autologous blood cells as the basis for a sensitive immunotoxicity/ hypersensitivity platform which accurately predicts human immune responses. Our advantages: Does not rely on 2D cultures of cells. Our dynamic assay is capable of a wide array of readouts. Saves time and money in product development compared to other available tests. Capable of distinguishing the type of hypersensitivity reaction. Readouts include cytokine release, immunohistochemistry and histopathology. Contact us for more information
-
-
Did you know that we don't only work in pharmaceutical safety?! One of our early papers was looking at applying out data to understand the safety of personal care and cosmetic products on the skin! Standardised tests for skin irritation do not include an immune component and generally only look at the effect of a product on keratinocytes. Our assays contain all the cells normally found in the skin alongside the immune cells of the blood, creating a comprehensive way to model adverse toxicity in the skin. Get in touch! info@alcyomics.com #beauty #personalcare #claimvalidation #animalfreetesting #NAM #alternativemethods https://lnkd.in/etCFxpwy
An in vitro human assay for evaluating immunogenic and sensitization potential of a personal care and cosmetic product - PubMed
pubmed.ncbi.nlm.nih.gov
-
Alcyomics reposted this
New publication alert! 📢 ❗ In our fourth publication this year! Learn more about the validatory study we did with the Skimune assay for the detection and characterisation of adverse immunological events for biologics. In particular, see how our assay was able to efficient pick up reactions to TGN1412, demonstrating how using our approach can avoid costly mistakes in the clinic! #publication #anotherone? #safety #biologics #largemolecules https://lnkd.in/d2Nj35Ap
An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics
mdpi.com
-
New publication alert! 📢 ❗ In our fourth publication this year! Learn more about the validatory study we did with the Skimune assay for the detection and characterisation of adverse immunological events for biologics. In particular, see how our assay was able to efficient pick up reactions to TGN1412, demonstrating how using our approach can avoid costly mistakes in the clinic! #publication #anotherone? #safety #biologics #largemolecules https://lnkd.in/d2Nj35Ap
An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics
mdpi.com
-
On target off tumour toxicity is a critical issue when considering pharmaceutical safety. Many targets associated with certain cancers are also highly expressed in the skin such as EGFR and HER2. As such understanding the potential for skin reactivity in particular is of major importance when developing these therapies. Our Skimune assay uses both the tissue and blood from the same volunteer to provide critical information on on target off tumour toxicity within the skin. Get in touch to learn more!
-
Are you working on an immune cell engaging compound? Many immune cell engaging compounds target epitopes which are also widely expressed in the skin. Understanding the potential for off target toxicity is critical to ensure patient safety and clinical trial success! Alcyomics's Skimune assay combines skin tissue with immune cells from the same donor. This creates a powerful tool which we have shown predicts skin based toxicities, allows to understand the mechanism behind the reaction (quantification of target expression, immune cell colocalization, characterisation of tissue damage, and prediction of clinical response). Reach out to matthew.freer@alcyomics.com to learn more and to schedule a meeting! www.alcyomics.com #immuneengagers #tcellengagers #immunotherapy #safetyprediction
-